Aurion Biotech Announces Two Key Leadership Appointments

Published on April 24, 2025
SEATTLE, CAMBRIDGE, Mass. and TOKYO—Aurion Biotech, a clinical-stage regenerative medicine company focused on developing therapies for ocular diseases, has announced the appointments of Edward J. Holland, MD, as chief medical officer (CMO), and Eris P. Jordan, OD, as chief development officer. Both appointments are effective immediately. Dr. Holland replaces Michael Goldstein as CMO while Dr. Jordan’s position as chief development officer is a new leadership position at the company.
Continue reading on website
Other news

6 Mimickers of a 6th Cranial Nerve Palsy

April 23, 2025
The abducens nerve (6th cranial nerve) controls a single extraocular muscle; the lateral rectus. The lateral rectus is primarily responsible for abducting the eye. A palsy of the abducens nerve is the most common ocular motor paralysis; the affected eye turns inward toward the nose and is unable to abduct properly.The deviation is constant and is typically greater at distance fixation than at near

The optometrist’s role in managing age-related macular degeneration with OCT-A

April 24, 2025
The leading source of breaking news, news analysis, and emerging research reports in optometry, Optometry Times® disseminates practical content by optometrists for optometrists that can be immediately applied to improve the clinical experience.